恆瑞醫藥(600276.SH)子公司SHR0302鹼軟膏獲臨牀試驗通知書
格隆匯10月24日丨恆瑞醫藥(600276.SH)公佈,公司子公司瑞石生物醫藥有限公司近日收到國家藥監局核准簽發的SHR0302鹼軟膏《臨牀試驗通知書》。
SHR0302鹼是一種小分子JAK1激酶選擇性抑制劑,擬適用於特應性皮炎的治療。經查詢,國內外尚無JAK激酶抑制劑外用製劑獲批用於特應性皮炎的治療。國內外目前有包括蘆可替尼(Ruxolitinib)、Delgocitinib等多個JAK激酶抑制劑處於臨牀試驗階段。截至目前,SHR0302項目已投入研發費用約為9 863萬元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.